Tempus Software

Tempus is a health technology company founded in 2015 by Eric Lefkofsky. Headquartered in Chicago, Illinois, Tempus leverages artificial intelligence and machine learning to transform the field of personalized medicine. The company's mission is to collect and analyze clinical and molecular data at scale, thereby empowering healthcare providers to make data-driven decisions for optimal patient outcomes.

Tempus Solutions

xT Platform

The cornerstone of Tempus' offerings is the xT Platform, a robust tool for extensive molecular profiling combined with clinical data. This platform identifies targeted therapies and clinical trials for a broad range of cancer patients. By performing paired tumor/normal plus transcriptome sequencing, the xT Platform outperforms traditional tumor-only DNA panel testing. This capacity makes it a valuable resource for oncologists seeking to personalize cancer treatments.

Tempus xR

Tempus also introduced the standalone RNA next-generation sequencing assay, Tempus xR. This comprehensive whole transcriptome panel is designed for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes. It also identifies altered splicing for genes such as MET Exon 14 and EGFRvIII, providing actionable insights for clinicians.

Tempus One

Incorporating advancements in generative AI, Tempus One serves as an AI-enabled clinical assistant. This tool provides clinicians with instant access to patient insights, acting as a bridge between raw data and actionable medical information. By leveraging Tempus One, healthcare providers can make informed decisions at the point of care.

Founding and Leadership

Eric Lefkofsky, a serial entrepreneur, founded Tempus after his wife was diagnosed with cancer. Lefkofsky's vision was to create a platform that integrates large-scale clinical and molecular data to advance the field of precision medicine. Before Tempus, Lefkofsky co-founded companies such as Groupon, Echo Global Logistics, and InnerWorkings.

Brad Keywell, another co-founder of Groupon, is an early investor in Tempus. Keywell is also the chairman of Uptake Technologies, an industrial AI software provider, illustrating his vested interest in the application of AI across various industries.

Partnerships and Collaborations

Tempus collaborates with numerous healthcare institutions, research organizations, and pharmaceutical companies to augment its data repository and enhance its analytical capabilities. These partnerships facilitate the development of novel diagnostics and therapeutics, contributing to the broader goal of advancing personalized medicine.

Impact on Healthcare

Tempus is transforming the healthcare landscape by integrating comprehensive genomic data with advanced analytics. This integration enables the identification of unique biomarkers and the development of tailored treatment plans, thereby improving patient outcomes. Through its innovative software solutions, Tempus is at the forefront of the shift from a one-size-fits-all approach to a more individualized form of medical care.